A5006132661- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Organ Transplantation Techniques and Outcomes
- Lung Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Treatment and Pharmacology
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Liver Disease and Transplantation
- Neuroendocrine Tumor Research Advances
- Virus-based gene therapy research
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Dialysis and Renal Disease Management
- Phagocytosis and Immune Regulation
- Congenital Anomalies and Fetal Surgery
- Radiomics and Machine Learning in Medical Imaging
- Cancer therapeutics and mechanisms
- Breast Cancer Treatment Studies
- Parasitic infections in humans and animals
Japan Medical Association
2024
Kyoto Prefectural University of Medicine
2016-2023
Peking University
2021-2022
Peking University Cancer Hospital
2021-2022
National Clinical Research Center for Digestive Diseases
2022
Central South University
2022
Fujian Medical University
2022
Union Hospital
2022
Xiangya Hospital Central South University
2022
Zhongshan Hospital
2019
A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback loop. Activated was associated EGFR HER3 maintaining cell survival inducing the emergence of cells tolerant inhibition reduced viability cancer overexpressing were exposed The addition during either...
BACKGROUND Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common patients with advanced cancer. This study examined the efficacy safety of anamorelin (ONO‐7643), a novel selective ghrelin receptor agonist, Japanese cancer cachexia. METHODS double‐blind clinical trial (ONO‐7643‐04) enrolled 174 unresectable stage III/IV non–small cell lung (NSCLC) cachexia Japan. Patients were randomized to daily oral (100 mg) or placebo for 12 weeks. The primary endpoint...
Long-Evans Cinnamon (LEC) rats, an inbred strain of a mutant rat isolated from develop hereditary hepatitis. To elucidate the role copper metabolism in development hepatitis LEC we examined concentration tissues and serum levels ceruloplasmin. Copper liver rats was over 40 times that normal Agouti (LEA) while ceruloplasmin concentrations decreased significantly. The hepatocytes show steatosis cytoplasm pleomorphism mitochondria, resembling histologic features Wilson's disease. These findings...
Abstract Purpose: Currently, an optimal therapeutic strategy comprising molecularly targeted agents for treating EGFR-mutated non–small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib is not available. Therefore, the initial intervention crucial prolonged survival of these patients. The activation anexelekto (AXL) signaling known be associated intrinsic and EGFR tyrosine kinase inhibitors (EGFR-TKIs). In this study, we investigated best combat AXL-induced tolerance...
Abstract Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients EGFR ‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation NSCLC mutations who exhibit clinical outcomes that require treatment immune checkpoint (ICIs). Therefore, identify eligible cases treat ICIs, we retrospectively analyzed correlation between features and efficacy ICIs mutations. Patients Methods...
Secondary sarcopenia is defined as a decrease in muscle mass due to disease or malnutrition. Several studies have reported that secondary an indicator of postoperative recurrence. We hypothesized there correlation between the effect immune checkpoint inhibitors (ICIs) and sarcopenia. retrospectively analyzed 38 patients with advanced non-small cell lung cancer (NSCLC) who were treated ICIs February 2016 April 2018. Patients divided into two groups according change rate psoas major area...
Background: Cancer immunotherapy is being developed as a promising alternative for advanced non-small cell lung cancer (NSCLC). However, novel biomarkers are required to select patients that will benefit from treatment with immune checkpoint inhibitors (ICIs) long period of time. The gut microbiome expected be biomarker ICI response owing the regulation status within host.
Little is known regarding the effectiveness and tolerability of immune checkpoint inhibitor (ICI) rechallenge after disease progression following initial ICI treatments. To identify eligible patients for rechallenge, we retrospectively analyzed relationship between clinical profiles effect in with non-small cell lung cancer (NSCLC). We enrolled 35 NSCLC at six different institutions who were retreated ICIs discontinued treatments due to progression. Cox proportional hazards models used...
Cancer cachexia is a syndrome characterized by anorexia and decreased body weight. This study evaluated the efficacy safety of anamorelin, an orally active, selective ghrelin receptor agonist, in patients with cancer low mass index (BMI).This multicenter, open-label, single-arm enrolled Japanese non-small cell lung or gastrointestinal (BMI < 20 kg/m2 , involuntary weight loss > 2% last 6 months, anorexia). Patients were administered 100 mg anamorelin once daily for up to 24 weeks. The...
Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated significantly better survival outcomes than alone in patients advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The nutritional index (PNI) (LIPI) biomarkers inhibitor (ICI) monotherapy or chemotherapies. Thus, we aimed to examine whether these factors could also be We retrospectively examined 237 NSCLC treated In...
Programmed cell death protein-1 (PD-1) blockade therapy has improved outcomes in the treatment of advanced cancers. The is well-tolerated, although it occasionally causes immune-related adverse events (irAEs). Thyroid dysfunction one most common irAEs seen. Our aim was to clarify clinical characteristics thyroid induced by PD-1 and its association with therapeutic effect A total 174 patients who received nivolumab or pembrolizumab for metastatic unresectable cancers were included this...
Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of on chemoimmunotherapy unclear. We investigated therapeutic outcomes non-small cell lung (NSCLC). retrospectively analyzed patients' medical records with NSCLC who received in 12 institutions Japan between January and November 2019. defined as weight loss exceeding 5% total body or mass index < 20 kg/m2 more than 2% within 6 months before initiation,...
Abstract Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have shown dramatic efficacy in patients with ALK-rearranged lung cancer; however, complete response these is rare. Here, we investigated the molecular mechanisms underlying emergence and maintenance of drug-tolerant cells cancer. Cell based-assays demonstrated that HER3 activation mesenchymal-to-epithelial transition, mediated through ZEB1 proteins, help maintain cell survival induce ALK-TKI-tolerant cells. Compared...
The Cardio-Ankle Vascular Index (CAVI) is a stiffness index of the arterial tree from origin aorta to ankle, independent blood pressure at time measurement. CAVI equation includes coefficients "a" and "b" adjust it value Hasegawa's pulse wave velocity, which compensated for 80 mmHg diastolic pressure. To verify this adjustment with coefficients, clinical significance without (haβ) were compared in both an epidemiological study acute study.In study, significances haβ among people or coronary...